Table 1

Baseline Characteristics

All Patients (N = 129)Retrospective Cohort (n = 76)Validation Cohort (n = 53)p Value (Retrospective vs. Validation)
Age, yrs66 ± 867 ± 865 ± 90.20
Male, %6459700.22
Arterial hypertension, %6763740.22
SHD, %3329400.21
CHA2DS2VASc score2.4 ± 1.62.5 ± 1.62.2 ± 1.50.31
Persistent AF, %8387770.16
Redo procedure, %7276660.20
LA size, mm45 ± 645 ± 744 ± 50.40
LVEF, %55 ± 955 ± 955 ± 90.86
AML localization, %
 To LSPV1412170.99
 To roof line4444430.99
 To RSPV4244400.99
AML indication
 Perimitral flutter, %5050510.92
 Substrate based, %505049
Cycle length of perimitral flutter, ms285 ± 52276 ± 53296 ± 490.16
Bidirectional AML block, %8584870.69
AML block directly visible, %2921420.01
RF time for AML ablation, min9 (6–14)9 (6–14)8 (6–14)0.71
Roof line, %6265590.49
CTI, %4650400.29
Additional ablation of AT, %4243400.67
Electrical cardioversion during procedure, %9119<0.001

Values are mean ± SD or median (interquartile range) unless otherwise indicated.

AF = atrial fibrillation; AML = anterior mitral line; AT = atrial tachycardia; CTI = cavotricuspid isthmus; LA = left atrial; LSPV = left superior pulmonary vein; LVEF = left ventricular ejection fraction; RF = radiofrequency; RSPV = right superior pulmonary vein; SHD = structural heart disease.